<DOC>
	<DOCNO>NCT00214110</DOCNO>
	<brief_summary>This single-center , phase 2 randomized clinical trial tamoxifen mean percent predict isometric muscle strength patient amyotrophic lateral sclerosis ( ALS ) . The purpose determine whether triphenylethylenetamoxifen , use adjuvant therapy treatment breast cancer , delay loss isometric muscle strength ALS patient .</brief_summary>
	<brief_title>Tamoxifen Therapy Amyotrophic Lateral Sclerosis ALS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>clinically probablelaboratory support , clinically probable , clinically definite amyotrophic lateral sclerosis Allergic idiosyncratic response tamoxifen . Other active neurologic disease may produce weakness , sensory loss , autonomic symptom . Psychiatric , psychological , behavioral symptom would interfere subject 's ability participate trial . Clinically significant cardiac , pulmonary , gastrointestinal , hematologic , endocrine ( poorly control insulindependent diabetes mellitus hyperthyroidism ) disease may confound interpretation study result . Previous kidney pancreas transplant . Significant hepatic renal disease ( AST &gt; 5 time normal , serum creatinine &gt; 2.0 mg/dL male &gt; 1.8 mg/dL female ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>